Literature DB >> 21045798

Use of botulinum toxin in the neurology clinic.

Erle C H Lim1, Raymond C S Seet.   

Abstract

Botulinum neurotoxin (BoNT) is an effective treatment for conditions associated with overactivity of glandular, smooth or skeletal muscle, and this toxin can also ameliorate certain painful conditions. Electromyography, endoscopy and imaging techniques such as ultrasonography and fluoroscopy have been used to increase the accuracy of BoNT injections. This Review assesses the mechanisms of action of BoNT, and examines the use of BoNT injections in numerous neurological conditions, including dystonia, spasticity, headaches and other painful disorders, hemifacial spasm, essential tremor, motor tics, hyperhidrosis, and sialorrhea and drooling. Important practical aspects, such as the reconstitution of BoNT, dosing, and methods of administration, are also addressed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21045798     DOI: 10.1038/nrneurol.2010.149

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN: 1759-4758            Impact factor:   42.937


  124 in total

Review 1.  Botulinum toxin in clinical practice.

Authors:  J Jankovic
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-07       Impact factor: 10.154

2.  Electromyographic evaluation of cervical dystonia for planning of botulinum toxin therapy.

Authors:  D Dressler
Journal:  Eur J Neurol       Date:  2000-11       Impact factor: 6.089

3.  Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study.

Authors:  W J Binder; M F Brin; A Blitzer; L D Schoenrock; J M Pogoda
Journal:  Otolaryngol Head Neck Surg       Date:  2000-12       Impact factor: 3.497

4.  Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: a 52-week multicenter double-blind, randomized, placebo-controlled study of efficacy and safety.

Authors:  Nicholas J Lowe; Dee Anna Glaser; Nina Eadie; Simon Daggett; Jonathan W Kowalski; Pan-Yu Lai
Journal:  J Am Acad Dermatol       Date:  2007-02-15       Impact factor: 11.527

5.  Treatment with botulinum toxin in a patient with myasthenia gravis and cervical dystonia.

Authors:  A Fasano; A R Bentivoglio; T Ialongo; F Soleti; A Evoli
Journal:  Neurology       Date:  2005-06-28       Impact factor: 9.910

Review 6.  Botulinum neurotoxins in the treatment of refractory pain.

Authors:  Bahman Jabbari
Journal:  Nat Clin Pract Neurol       Date:  2008-12

Review 7.  Use of botulinum toxin A in adult neurological disorders: efficacy, tolerability and safety.

Authors:  Wilhelm J Schulte-Mattler
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

8.  Assay of diffusion of different botulinum neurotoxin type a formulations injected in the mouse leg.

Authors:  Luca Carli; Cesare Montecucco; Ornella Rossetto
Journal:  Muscle Nerve       Date:  2009-09       Impact factor: 3.217

9.  Migraine prophylaxis with botulinum toxin A is associated with perception of headache.

Authors:  Rami Burstein; David Dodick; Stephen Silberstein
Journal:  Toxicon       Date:  2009-01-22       Impact factor: 3.033

Review 10.  Botulinum toxins in the treatment of migraine and tension-type headaches.

Authors:  Paul Winner
Journal:  Phys Med Rehabil Clin N Am       Date:  2003-11       Impact factor: 1.784

View more
  22 in total

Review 1.  Botulinum neurotoxins: genetic, structural and mechanistic insights.

Authors:  Ornella Rossetto; Marco Pirazzini; Cesare Montecucco
Journal:  Nat Rev Microbiol       Date:  2014-06-30       Impact factor: 60.633

2.  Positive regulation of botulinum neurotoxin gene expression by CodY in Clostridium botulinum ATCC 3502.

Authors:  Zhen Zhang; Elias Dahlsten; Hannu Korkeala; Miia Lindström
Journal:  Appl Environ Microbiol       Date:  2014-10-03       Impact factor: 4.792

Review 3.  Nerve Compression Syndromes in the Posterior Cranial Fossa.

Authors:  Jörg Baldauf; Christian Rosenstengel; Henry W S Schroeder
Journal:  Dtsch Arztebl Int       Date:  2019-01-25       Impact factor: 5.594

4.  Selective and sustained α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor activation in cerebellum induces dystonia in mice.

Authors:  Xueliang Fan; Keryn E Hughes; H A Jinnah; Ellen J Hess
Journal:  J Pharmacol Exp Ther       Date:  2011-12-14       Impact factor: 4.030

Review 5.  Update on treatments for dystonia.

Authors:  D Cristopher Bragg; Nutan Sharma
Journal:  Curr Neurol Neurosci Rep       Date:  2014-06       Impact factor: 5.081

6.  Use of botulinum toxin type A in the management of patients with neurological disorders: a national survey.

Authors:  Nicola Smania; Carlo Colosimo; Anna Rita Bentivoglio; Giorgio Sandrini; Alessandro Picelli
Journal:  Funct Neurol       Date:  2013 Oct-Dec

7.  Nuclear envelope budding enables large ribonucleoprotein particle export during synaptic Wnt signaling.

Authors:  Sean D Speese; James Ashley; Vahbiz Jokhi; John Nunnari; Romina Barria; Yihang Li; Bulent Ataman; Alex Koon; Young-Tae Chang; Qian Li; Melissa J Moore; Vivian Budnik
Journal:  Cell       Date:  2012-05-11       Impact factor: 41.582

Review 8.  The "Visible" Muscles on Ultrasound Imaging Make Botulinum Toxin Injection More Precise: A Systematic Review.

Authors:  Zhijin Li; Yanlong Yang; Nanze Yu; Wenzhe Zhou; Zirong Li; Yuming Chong; Yuwei Zhang; Hayson Chenyu Wang; Cheng Chen; Xiao Long; Xiaojun Wang
Journal:  Aesthetic Plast Surg       Date:  2021-08-02       Impact factor: 2.326

9.  Isolation of a nanomolar scFv inhibiting the endopeptidase activity of botulinum toxin A, by single-round panning of an immune phage-displayed library of macaque origin.

Authors:  Siham Chahboun; Michael Hust; Yvonne Liu; Thibaut Pelat; Sebastian Miethe; Saskia Helmsing; Russell Ga Jones; Dorothea Sesardic; Philippe Thullier
Journal:  BMC Biotechnol       Date:  2011-11-23       Impact factor: 2.563

10.  Two-component signal transduction system CBO0787/CBO0786 represses transcription from botulinum neurotoxin promoters in Clostridium botulinum ATCC 3502.

Authors:  Zhen Zhang; Hannu Korkeala; Elias Dahlsten; Elina Sahala; John T Heap; Nigel P Minton; Miia Lindström
Journal:  PLoS Pathog       Date:  2013-03-28       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.